Skip to main content

Fiscal Wizard · Single-issue tearsheet

ARWR / Jun 21, 2026 Run #7402

ARWR

Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Composite verdict

A 86.5 / 100
Bullish setup · Trend Following 18 drivers · 3 gates blocking
  • 52-Week Proximity
  • Parabolic SAR Flip
  • Elder Force Index
Consider long call target Δ ~0.70 · ~35 DTE Bullish setup, Grade A → ITM call target

Industry rank 8th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 100%Evidence: High · 23 signals0% Bear
Momentum Bullish 93Mean-reversion Neutral 53

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from
Asset value $3.31Earnings power value $3.54Price $81.82

Priced above its no-growth earnings power value ($3.54/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Strong

73.0 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Days Sales Outstanding 100
Free Cash Flow Yield 5
EPS Growth (YoY) 100
P/S Ratio 25
Revenue Growth (YoY) 100
P/B 25

Technicals Bullish

100.0 / 100

Bullish setup leads (52-Week Proximity, Parabolic SAR Flip, Elder Force Index); bears gated by guards. · 43 signals shown.

Strongest
Weakest
52-Week Proximity 92
Rate of Change 90
Chaikin Money Flow 89

Risk Gates

3 blocking 6 caution

3 guards active, 15 signals gated.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for ARWR.